help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lam, K. S.-L.
Right arrow Articles by Tam, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lam, K. S.-L.
Right arrow Articles by Tam, S.
The Journal of Clinical Endocrinology & Metabolism Vol. 89, No. 11 5448-5453
Copyright © 2004 by The Endocrine Society

Serum Adiponectin Is Reduced in Acromegaly and Normalized after Correction of Growth Hormone Excess

Karen Siu-Ling Lam, Aimin Xu, Kathryn Choon-Beng Tan, Lai-Ching Wong, Sau-Cheung Tiu and Sidney Tam

Department of Medicine, University of Hong Kong (K.S.-L.L., A.X., K.C.-B.T., L.-C.W.); Department of Medicine, Queen Elizabeth Hospital (S.-C.T.); and Clinical Biochemistry Unit, Queen Mary Hospital (S.T.), Hong Kong

Address all correspondence and requests for reprints to: Dr. Karen Lam, Department of Medicine, University of Hong Kong, Queen Mary Hospital, Pokfulam Road, Hong Kong. E-mail: ksllam{at}hkucc.hku.hk.

Adiponectin, an adipocyte-derived hormone, possesses insulin-sensitizing, antiinflammatory, and antiatherogenic properties. We hypothesized that hypoadiponectinemia was present in acromegaly, as in other conditions with increased insulin resistance and cardiovascular risk. Using an in-house RIA, serum adiponectin was determined in 35 patients with active acromegaly and 35 age-, sex-, and body mass index-matched healthy controls. Twenty-five patients were restudied after GH-lowering therapies. Serum adiponectin was significantly reduced in the acromegalic patients (4.3 ± 1.8 vs. 6.7 ± 1.8 µg/ml in controls; P < 0.001), but was increased after treatment with Sandostatin LAR, a long-acting somatostatin analog (5.8 ± 2.6 vs. 3.8 ± 1.6 µg/ml pretreatment; P < 0.001; n = 15) or transsphenoidal surgery (6.5 ± 2.7 vs. 3.9 ± 1.5 µg/ml preoperation; P < 0.01; n = 10). Fasting insulin was an independent determinant of serum adiponectin levels (P < 0.01) in control subjects, contributing to 11.7% of the variance in circulating adiponectin. In cultured 3T3-L1 adipocytes, adiponectin mRNA levels were decreased by insulin (1.5 µM; P < 0.005) or IGF-I (1 µg/ml; P < 0.05), but not by GH (1 µM) or somatostatin (1 µM). In conclusion, hypoadiponectinemia is present in active acromegaly, probably secondary to the inhibitory effect of high circulating insulin levels. Hypoadiponectinemia, reversible with GH-lowering therapies, may contribute to the increased insulin resistance and cardiovascular risk in patients with acromegaly.




This article has been cited by other articles:


Home page
J Gerontol A Biol Sci Med SciHome page
M. M. Masternak, J. A. Panici, F. Wang, Z. Wang, and A. Spong
The Effects of Growth hormone (GH) Treatment on GH and Insulin/IGF-1 Signaling in Long-Lived Ames Dwarf Mice
J Gerontol A Biol Sci Med Sci, November 11, 2009; (2009) glp172v1.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
N. Sucunza, M. J. Barahona, E. Resmini, J.-M. Fernandez-Real, W. Ricart, J. Farrerons, J. Rodriguez Espinosa, A.-M. Marin, T. Puig, and S. M. Webb
A Link between Bone Mineral Density and Serum Adiponectin and Visfatin Levels in Acromegaly
J. Clin. Endocrinol. Metab., October 1, 2009; 94(10): 3889 - 3896.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
Z. Wang, M. M. Masternak, K. A. Al-Regaiey, and A. Bartke
Adipocytokines and the Regulation of Lipid Metabolism in Growth Hormone Transgenic and Calorie-Restricted Mice
Endocrinology, June 1, 2007; 148(6): 2845 - 2853.
[Abstract] [Full Text] [PDF]


Home page
Journals of Gerontology Series A: Biological Sciences and Medical SciencesHome page
H. Yamaza, T. Komatsu, K. To, H. Toyama, T. Chiba, Y. Higami, and I. Shimokawa
Involvement of Insulin-Like Growth Factor-1 in the Effect of Caloric Restriction: Regulation of Plasma Adiponectin and Leptin
J. Gerontol. A Biol. Sci. Med. Sci., January 1, 2007; 62(1): 27 - 33.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
R. H. Willemsen, M. van Dijk, Y. B. de Rijke, A. W. van Toorenenbergen, P. G. Mulder, and A. C. Hokken-Koelega
Effect of Growth Hormone Therapy on Serum Adiponectin and Resistin Levels in Short, Small-for-Gestational-Age Children and Associations with Cardiovascular Risk Parameters
J. Clin. Endocrinol. Metab., January 1, 2007; 92(1): 117 - 123.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
M.-H. Gannage-Yared, S. Khalife, M. Semaan, F. Fares, S. Jambart, and G. Halaby
Serum adiponectin and leptin levels in relation to the metabolic syndrome, androgenic profile and somatotropic axis in healthy non-diabetic elderly men.
Eur. J. Endocrinol., July 1, 2006; 155(1): 167 - 176.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2004 by The Endocrine Society